Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

JNJ-7706621

HY-10329

(JNJ7706621; JNJ 7706621)

JNJ-7706621

JNJ-7706621 Chemical Structure

JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6; also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1.

Size Price Stock Quantity
10 mM * 1 mL in DMSO $178 In-stock
5 mg $162 In-stock
10 mg $297 In-stock
50 mg $702 In-stock
100 mg $1170 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
10 mM * 1 mL in DMSO €174 In-stock
5 mg €159 In-stock
10 mg €291 In-stock
50 mg €688 In-stock
100 mg €1147 In-stock
200 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: JNJ-7706621
Cat. No.: HY-10329

JNJ-7706621 Data Sheet

  • View current batch:

    Purity: 99.82%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

    Pdf Version

    NMR

    Pdf Version

    LCMS

Related Compound Libraries

Biological Activity of JNJ-7706621

JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6; also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1.
IC50 Value: 9 nM(CDK1/Cyclin B); 4 nM(CDK2/Cyclin A); 3 nM(CDK2/Cyclin E); 11 nM (Aurora-A)
Target: CDK1/2; Aurora A/B
in vitro: JNJ-7706621 shows some inhibition to VEGF-R2, FGF-R2, and GSK3β, with IC50 of 154-254 nM. JNJ-7706621 shows inhibitory effect on a panel of human cancer cell types, including HeLa, HCT-116, SK-OV-3, PC3, DU145, A375, MDA-MB-231, MES-SA, and MES-SA/Dx5, with IC50 of 112-514 nM, independent of p53, retinoblastoma, or P-glycoprotein status. JNJ-7706621 is several-fold less potent at inhibiting growth of normal cell types, including MRC-5, HASMC, HUVEC, and HMVEC, with IC50 of 3.67-5.42 μM. In HeLa or U937 cells, JNJ-7706621 (0.5-3 μM) delays exit from G1, arrests cells in G2-M, induces endoreduplication, activates apoptosis, and reduces colony formation. In a HeLa cell line, incremental treatment with increasing concentrations of JNJ-7706621 leads to a 16-fold resistance, which may be mediated by ABCG2.
in vivo: In mouse xenograft model of A375 melanoma human tumor, JNJ-7706621 (100 or 125 mg/kg) causes tumor regression.

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 394.36 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C15H12F2N6O3S
CAS No 443797-96-4
Solvent & Solubility

DMSO ≥75mg/mL Water <1.2mg/mL Ethanol ≥2.8mg/mL

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 2.5358 mL 12.6788 mL 25.3575 mL
5 mM 0.5072 mL 2.5358 mL 5.0715 mL
10 mM 0.2536 mL 1.2679 mL 2.5358 mL

References on JNJ-7706621

Inhibitor Kit

Related Aurora Kinase , CDK Products

  • Alisertib

    Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM; has >200-fold higher selectivity for Aurora A than Aurora B.

  • AMG 900

    AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A/B/C with IC50 of 5 nM/4 nM /1 nM; >10-fold selective for Aurora kinases than p38(alpha), Tyk2, JNK2, Met and Tie2.

  • AMG 925

    AMG 925 is a potent and selective dual inhibtor of CDK4/FLT3 with IC50s of 1.5 nM and 2.4 nM for CDK4 and FLT3, respectively; with IC50 of 19 nM in MOLM-13 cell.

  • AT9283

    AT9283 is a small molecule a multi-targeted inhibitor with IC50s of 4, 1.2, 1.1 and approximate 3 nM for Bcr-Abl(T3151), JAK2 and JAK3, Aurora A and Aurora B, respectively.

  • Aurora A inhibitor I

    Aurora A inhibitor I is a selective Aurora A inhibitor (Aurora A: IC50=0.0034 (mu)M; Aurora B IC50=3.4 (mu)M), (B/A ratio=1000).

  • AZD-5438

    AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM. It is less potent to CDK5/6.

  • AZD1152

    AZD1152 (barasertib), pro-drug of barasertib-hQPA(HY-10126), is a selective Aurora B kinase inhibitor, AZD1152 inhibited the proliferation various types of human leukemia cells with an IC50 ranging from 3 nM to 40 nM.

  • AZD1152-HQPA

    AZD1152-HQPA is the active metabolite of AZD-1152, AZD1152-HQPA (Barasertib) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM, ~100 fold more selective for Aurora B over Aurora A.

  • BIO

    6-BIO(6-Bromoindirubin-3(acute)-oxime) is a potent and selective inhibitor of GSK-3 and CDK1–cyclinB complex with IC50 of 5 nM /320 nM/83 nM for GSK-3(alpha)(beta)/CDK1/CDK5 respectively.

  • BMS-265246

    BMS-265246 is a potent and selective CDK1/2 inhibitor for CDK1/cyclin B and CDK2/cyclin E with IC50 of 6 nM and 9 nM, respectively.

MORE